Similarly, CK1α inhibition enhanced the effects of lenalidomide and bortezomib in multiple myeloma cells, resulting in increased apoptosis when compared to single agents, and, importantly, healthy B cells were unaffected [69]. This evidence concerns the gene CSNK1A1 and plasma cell myeloma.